The effectiveness of midodrine in reducing vasopressor use among patients with septic shock in the intensive care unit

A clinical trial comparing the effectiveness of midodrine versus standard care in reducing vasopressor use among patients with septic shock in the intensive care unit

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151108024938N4

Enrollment

Registered

2025-09-21

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic shock. Septic shock

Interventions

Intervention 1: Intervention group: In the intervention group, 24 hours after initiating norepinephrine therapy, patients will receive 5 mg of oral midodrine every 8 hours, while norepinephrine admini

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Receiving intravenous vasopressors Diagnosed with septic shock according to the Sepsis Campaign definition

Exclusion criteria

Exclusion criteria: Having study drugs allergies Use of midodrine within the past 7 days Bradycardia Using of monoamine oxidase inhibitors (MAOIs) Concurrent use of negative chronotropic agents Pregnancy APACHE II score less than 25 Patients undergoing dialysis

Design outcomes

Primary

Measure	Time frame
ICU length of stay. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.;Duration of intravenous vasopressor therapy. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.;Total hospital length of stay. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.;60-day mortality. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.	—

Measure

Time frame

ICU length of stay. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.;Duration of intravenous vasopressor therapy. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.;Total hospital length of stay. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.;60-day mortality. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.

—

Secondary

Measure	Time frame
ICU readmission rate. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.;Re-initiation rate of intravenous vasopressor therapy. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.;Adverse effects of midodrine. Timepoint: 60 days after intervention. Method of measurement: Observe the occurrence.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Sedaghat

Mashhad University of Medical Sciences

sedaghatar@mums.ac.ir+98 51 3802 3701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026